<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308916</url>
  </required_header>
  <id_info>
    <org_study_id>S-20170087</org_study_id>
    <nct_id>NCT03308916</nct_id>
  </id_info>
  <brief_title>Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers</brief_title>
  <acronym>SIPHON</acronym>
  <official_title>Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maja Thiele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission, H2020</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Esbjerg University Hospital of South-West Jutland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense Municipality Alcohol Rehabilitation Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Svendborg Municipality Alcohol Rehabilitation Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>VLV Bio, Peviva AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manatee APS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Siemens Healthcare A/S</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biomedical Research Foundation, Academy of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Molecular Biology Laboratory, EMBL, University of Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective screening study at Odense University Hospital to assess the effect of transient
      elastography and other serum and imaging markers of liver fibrosis to detect advanced
      fibrosis (Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver
      disease, alcoholic fatty liver disease, with a control group of participants recruited from
      the general population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol describes a prospective screening study at Odense University Hospital,
      Department of Gastroenterology and Hepatology. The investigators will use liver stiffness
      measurements with transient elastography to screen 3000 patients from at-risk populations and
      1000 participants from the general population for advanced liver fibrosis. At-risk is defined
      as either (A) a prior or current alcohol overuse (≥21 units/week for men and ≥14 units/week
      for women) for more than 5 years, or (B) presence of the metabolic syndrome with or without
      concomitant type 2 diabetes mellitus.

      The study goal is to evaluate the aptitude of transient elastography as a screening tool for
      advanced liver fibrosis, based on analyses of benefit, harm, detection rate, technical
      applicability and prognostic potential. Secondary aims are to compare novel serum markers of
      liver fibrosis as potential screening tools against transient elastography: The Enhanced
      Liver Fibrosis test, neoepitope markers of extracellular matrix turnover, cytokeratin-18
      based markers and indirect indices of fibrosis from algorithms combining routine liver blood
      test. Screened patients with elevated liver stiffness (≥8.0 kiloPascal; estimated 200
      patients with alcoholic liver disease, 400 patients with non-alcoholic fatty liver disease
      and 80 patients from the general population) will be investigated with 2-dimensional
      shear-wave elastography and abdominal ultrasonography and a liver biopsy to confirm or reject
      presence of advanced fibrosis. Participants with a positive screening elastography will be
      followed for disease progression with repeated liver stiffness measurements and serum
      fibrosis markers after one year. All participants will be followed for 10 years to assess
      liver-related outcomes and all-course mortality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2032</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single intervention group selected for screening with a historical control group</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy-verified advanced fibrosis</measure>
    <time_frame>5 years</time_frame>
    <description>Number of patients with biopsy-verified, advanced fibrosis (Kleiner fibrosis score ≥F3) detected by screening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver-related outcomes</measure>
    <time_frame>10 years</time_frame>
    <description>Number of liver-related clinical outcomes during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). Liver-related outcomes are defined as liver-related death, liver transplant, progression to liver-related complications (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, jaundice, bleeding from esophagastric varices, hepatocellular carcinoma) or MELD-Na score &gt;15</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver related outcomes</measure>
    <time_frame>10 years</time_frame>
    <description>Number of liver-related clinical outcomes during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts). Liver-related outcomes are defined as liver-related death, liver transplant, progression to liver-related complications (ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, jaundice, bleeding from esophagastric varices, hepatocellular carcinoma) or MELD-Na score &gt;15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>10 years</time_frame>
    <description>Overall number of deaths during 10 years of follow up after the first screened patient, compared to a matched, historical control group (The Inter99 study and the Copenhagen and Odense alcohol rehabilitation cohorts).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Liver Diseases, Alcoholic</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Liver stiffness measurement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transient elastography in fasting state</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>transient elastography</intervention_name>
    <description>Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis</description>
    <arm_group_label>Liver stiffness measurement</arm_group_label>
    <other_name>FibroScan</other_name>
    <other_name>TE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Enhanced liver fibrosis test</intervention_name>
    <description>Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)</description>
    <arm_group_label>Liver stiffness measurement</arm_group_label>
    <other_name>ELF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Indirect serum markers of liver fibrosis</intervention_name>
    <description>Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT</description>
    <arm_group_label>Liver stiffness measurement</arm_group_label>
    <other_name>Forns index</other_name>
    <other_name>FIB-4</other_name>
    <other_name>APRI</other_name>
    <other_name>AST-ALT ratio</other_name>
    <other_name>Age-platelet ratio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Direct serum markers of liver fibrosis</intervention_name>
    <description>Serum markers that reflect liver extracellular matrix turnover and -accumulation</description>
    <arm_group_label>Liver stiffness measurement</arm_group_label>
    <other_name>Neoepitopes</other_name>
    <other_name>Collagen products</other_name>
    <other_name>Extracellular matrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LiverTRAIL</intervention_name>
    <description>Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.</description>
    <arm_group_label>Liver stiffness measurement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cytokeratin 18</intervention_name>
    <description>Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)</description>
    <arm_group_label>Liver stiffness measurement</arm_group_label>
    <other_name>CK18</other_name>
    <other_name>M30</other_name>
    <other_name>M65</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Omics markers</intervention_name>
    <description>Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies</description>
    <arm_group_label>Liver stiffness measurement</arm_group_label>
    <other_name>Multi-omics markers</other_name>
    <other_name>Lipidomics</other_name>
    <other_name>Microbiomics</other_name>
    <other_name>Genomics</other_name>
    <other_name>Metagenomics</other_name>
    <other_name>Metatranscriptomics</other_name>
    <other_name>Transcriptomics</other_name>
    <other_name>miRNA-omics</other_name>
    <other_name>Metabolomics</other_name>
    <other_name>Proteomics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

        Patients are eligible for screening if the following inclusion criteria are fulfilled:

          -  Age 30-75 years (except the general population, which should be aged 45-75)

          -  Informed consent to study investigations

          -  Ability to read and write Danish AND (only at-risk patients)

          -  Prior or current alcohol overuse, defined as an average intake of ≥24 grams/day (14
             units/week) for women and ≥36 grams/day (21 units/week) for men, for at least 5 years;
             OR

          -  Presence of the metabolic syndrome defined by central obesity plus any two of the
             following four metabolic risk factors: (a) raised triglycerides, (b) reduced HDL
             cholesterol, (c) raised blood pressure and (d) raised fasting plasma glucose;[38] OR

          -  Type 2 diabetes mellitus defined by either fasting plasma glucose ≥7 mmol/L, HbA1c ≥48
             mmol/mol, a random plasma glucose ≥11.1 mmol/L in the presence of classic diabetes or
             an oral glucose tolerance test with fasting plasma glucose ≥7.0 mmol/L and/or 2 hour
             plasma glucose ≥11.1 mmol/L.

        EXCLUSION CRITERIA

        We will exclude patients from screening in case of:

          -  Evidence of decompensated liver disease, defined by clinically obvious ascites, overt
             hepatic encephalopathy, jaundice or large esophageal varices with/without variceal
             bleeding.

          -  Known concurrent liver disease other than ALD and NAFLD.

          -  Cancer or other debilitating disease with an expected survival of less than 12 months.

          -  Inability to comply with the study protocol.

        In screened patients with liver stiffness ≥8 kPa we will abstain from a liver biopsy in
        case of:

          -  Contraindications for a percutaneous liver biopsy

          -  Severe alcoholic hepatitis or other hepatic inflammation evidenced by transaminase
             elevation of more than three times the upper limit of normal.

          -  Hepatic congestion or bile duct dilation evidenced by ultrasound.

          -  Decrease of TE below 8.0 kPa from screening to time of planned liver biopsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Thiele, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastroenterology and Hepatology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Kjaergaard, MD</last_name>
    <phone>+4528345541</phone>
    <email>maria.kjaergaard@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maja Thiele, MD, PhD</last_name>
    <phone>+4524998068</phone>
    <email>maja.thiele@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maja Thiele, MD, PhD</last_name>
      <phone>65412752</phone>
      <phone_ext>45</phone_ext>
      <email>maja.thiele@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Maja Thiele, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksander Krag, MD PhD Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Maja Thiele</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>elastography</keyword>
  <keyword>screening</keyword>
  <keyword>non-invasive markers</keyword>
  <keyword>microbiome</keyword>
  <keyword>gut-liver-axis</keyword>
  <keyword>cost-benefit</keyword>
  <keyword>fibroscan</keyword>
  <keyword>aixplorer</keyword>
  <keyword>ultrasound elastography</keyword>
  <keyword>liver fibrosis</keyword>
  <keyword>alcoholic liver disease</keyword>
  <keyword>advanced fibrosis</keyword>
  <keyword>enhanced liver fibrosis test</keyword>
  <keyword>direct liver fibrosis markers</keyword>
  <keyword>ELF</keyword>
  <keyword>cytokeratin-18</keyword>
  <keyword>neoepitopes</keyword>
  <keyword>collagen</keyword>
  <keyword>NAFLD</keyword>
  <keyword>ALD</keyword>
  <keyword>metabolomics</keyword>
  <keyword>non-alcoholic fatty liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>OPEN - Odense Patient Exploratory data Network, managed by Odense University Hospital</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

